Details 1.Patients (between the ages of 8 to 65 years) with histologically proven high grade osteosarcoma of the extremity and relapsed disease after primary line of treatment who are unsuitable or refuse secondary chemotherapy.
3.Patients with early or non-metastatic disease who are unable or unwilling to take the standard chemotherapy.
Details 1.Patients who are suitable for second line chemotherapy and can afford it 2.Age less than 8 years or greater than 65 years 3.Pregnant or lactating women 4.Patients who are unable or unwilling to provide blood samples for the drug assays. 5.Low grade osteosarcoma 6.Participation in any investigational drug study within 28 days prior to study treatment.
Final Enrollment numbers achieved (Total)= ""
Final Enrollment numbers achieved (India)=""
Modification(s) Curcumin as well as the Ashwagandha extract are ingredients from traditional Indian medicine and have been shown to be potent anti-cancer compounds in laboratory as well as animal studies. This is Non-Randomized Parallel group study.This study will test the safety and efficacy of a curcumin formulation and the Ashwagandha extract in high grade relapsed or metastatic osteosarcoma where no other second line chemotherapy is being given. The pharmacokinetics will be studied along with response as measured on CT scans and PET scans as well as the quality of life and any toxicity In both groups, the tablets will be given daily for 3 months if well tolerated. A CT chest and local x-rays will be done at 3 months and response will be assessed. If the response is good and there is no Dose limiting Toxicity (DLT), the medication will be continued for another 3 months.